PMEF
PSTX

Point72 Middle East FZE’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Point72 Middle East FZE’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,341
Closed -$17.9K – 1415
2023
Q4 		$17.9K Buy
+5,341
New +$13.8K ﹤0.01% 1366
2023
Q2 		– Sell
-7,860
Closed -$24.2K – 2148
2023
Q1 		$24.2K Buy
+7,860
New +$47.1K ﹤0.01% 1396

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Point72 Middle East FZE's PSTX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 5,341 shares — an estimated $17.9K sold.

Point72 Middle East FZE first reported a position in PSTX in Q1 2023 and held it in 2 quarters. The position peaked at $24.2K in Q1 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,341 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $17.9K.
  • Point72 Middle East FZE first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Poseida Therapeutics, Inc. Common Stock position peaked at $24.2K in Q1 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.